This article was originally published in Pharmaceutical Approvals Monthly
FDA is negotiating with Searle to change the misoprostol label to reflect the potential for use in the Mifeprex pregnancy-termination regimen, FDA Commissioner Jane Henney, MD, told a House Commerce/Oversight Subcommittee hearing Oct. 3. Pharmacia subsidiary Searle issued a "Dear Health Care Provider" letter in August emphasizing that its gastric ulcer treatment is contraindicated for use in pregnant women and not approved for induction of labor or abortion. Danco Labs expects Mifeprex to be available in late October, and FDA presumably would want to have Cytotec labeling updated for Mifeprex's launc
You may also be interested in...
Trial diversity is among the issues that stakeholders worry could hinder vaccine uptake.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
A study with nearly 500 patients with vitamin D levels tested within a year before receiving COVID-19 tests found subjects deficient in the nutrient had 1.77 greater chance of testing positive. Researchers say RCTs are needed to determine if broad population interventions are necessary.